, for patients treated with ibrutinib and chlorambucil. Neutropenia (13%), pneumonia (12%), hypertension (8%), and anemia (7%) were the common grade ≥3 adverse events. Ibrutinib also improved PFS compared with chlorambucil in patients with high-risk CLL
Search Results
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, and Hema Sundar
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar
statistically significant survival benefit compared with FC in patients aged <65 years (5-year OS, 80.9% and 69.2%, respectively; P =.002); corresponding 5-year OS rates were 73.9% and 61.6%, respectively ( P =.288). The incidence of prolonged neutropenia was
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer
included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar
study. The most common treatment-related toxicities were neutropenia (grade 3/4; 20%) and infections (any grade; 53%), including those requiring intravenous antibiotics (27%). In a study of 358 patients with untreated HCL, cladribine resulted in a CR
Emerging Therapies in the Treatment of Bladder Cancer
Presented by: Arlene O. Siefker-Radtke
govitecan may experience side effects. Neutropenia, including febrile neutropenia, and diarrhea, nausea, and vomiting were among the most frequently reported treatment-related adverse events in the study population. 10 “Patients with bladder cancer, in
Pertuzumab in the Treatment of HER2+ Breast Cancer
Komal Jhaveri and Francisco J. Esteva
neutropenia were noted in 2 of 2 patients treated with 75 mg/m 2 of docetaxel and 1050 mg of pertuzumab every 3 weeks. Of 5 patients, 2 who received 100 mg/m 2 of docetaxel and 420 mg of pertuzumab (after a loading dose of 840 mg) every 3 weeks experienced
Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma
Alessandra Larocca and Antonio Palumbo
very good partial response (VGPR) were particularly higher with RD, as was 1-year PFS. However, this improvement did not translate into an overall survival advantage. The incidences of grade 3/4 neutropenia (21% vs. 5%) and thromboembolic events (24% vs
New NCCN Guidelines: Cancer Management in People Living With HIV
Gita Suneja
, vinblastine, and dacarbazine) is recommended for treating HL in people with HIV infection. However, dose reductions may be required for prolonged severe neutropenia. 7 In this population, growth factors may be required for those with a low CD4-positive T
Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Presented by: Anthony Mato
differences in atrial fibrillation favoring zanubrutinib over ibrutinib (10.1% vs 2.5%), although neutropenia occurred more frequently in patients receiving zanubrutinib. Hypertension was the same with either agent. The ELEVATE-RR trial, which compared
Correspondence
Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky
alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We
